Clinical Analysis of Juvenile Dermatomyositis Patients

Study Overview
=================
Brief Summary
-----------------
This study aimed to investigate the clinical effectivity of intravenous methylprednisolone repeated intermittent pulse combined with mycophenolate mofetil in the treatment of newly diagnosed juvenile dermatomyositis.

Detailed Description
-----------------
Reviewed the clinical data of 12 juvenile dermatomyositis patients, from January 2014 to January 2017, hospitalized and treated with intravenous methylprednisolone repeated intermittent pulse combined with mycophenolate mofetil

Official Title
-----------------
Clinical Analysis of 12 Cases of Juvenile Dermatomyositis Treated With Methylprednisolone Repeated Intermittent Pulse Combined With Mycophenolate Mofetil

Conditions
-----------------
Juvenile Dermatomyositis

Intervention / Treatment
-----------------
* Other: observation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with age of JDM onset <16 years newly treated cases no contraindications to corticosteroids provide signed informed consent form regular follow-up for more than 30 months. Exclusion Criteria: patients with serious complications of heart, liver and kidney patients with a history of contraindications and/or allergies to GC patients who underwent treatment before admission patients who failed to regularly follow-up patients with positive anti-melanoma differentiation-associated gene 5 (MDA5) antibodies

Ages Eligible for Study
-----------------
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: observation|investigate the clinical effectivity of intravenous methylprednisolone repeated intermittent pulse combined with mycophenolate mofetil in the treatment of newly diagnosed juvenile dermatomyositis|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in CMAS score | CMAS score is an index to assess the disease activity of JDM | 1, 3, 6, 12, 18, 24 and 36 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes from baseline of the patient's height percentile in the same age and sex crowd. | the patient's height percentile in the same age and sex crowd is one of safety evaluation indicators. | 1, 3, 6, 12, 18, 24 and 36months | 
| Changes from baseline of the patient's weight percentile in the same age and sex crowd. | the patient's weight percentile in the same age and sex crowd is one of safety evaluation indicators. | 1, 3, 6, 12, 18, 24 and 36months | 
| intraocular pressure | the patient's intraocular pressure is one of safety evaluation indicators. | 1, 3, 6, 12, 18, 24 and 36months | 
| triglycerides | the patient's triglycerides is one of safety evaluation indicators. | 1, 3, 6, 12, 18, 24 and 36months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
intravenous methylprednisolone repeated intermittent pulse, mycophenolate mofetil